Non Invasive Prenatal Testing (NIPT) Market
The Global Non-invasive Prenatal Testing (NIPT) Market is estimated to be valued at USD 4.60 Bn in 2024 and is expected to reach USD 9.11 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 10.2% from 2024 to 2031.Global Non-invasive Prenatal Testing (NIPT) Market is used to screen fetal DNA in the mother's bloodstream to check if the fetus is at a high risk of genetic abnormalities without being invasive to the pregnancy or the fetus. These tests analyze cell-free DNA (cfDNA) from the placenta that circulates in the mother's bloodstream. They can check the risk of genetic conditions like Down’s syndrome, Trisomy 13, Trisomy 18, sex chromosome aneuploidies, and other abnormalities. With advancements in genomic technologies, NIPT has become one of the pioneering techniques used for prenatal screening and is gaining immense popularity among expectant mothers worldwide as it provides accurate results and avoids risks of miscarriage associated with invasive tests like amniocentesis.
Market Dynamics:
The global Non-invasive Prenatal Testing (NIPT) market is driven by factors such as increasing maternal age, rising incidence of babies born with Down’s syndrome, growing awareness about NIPT, and technological advancements in diagnostic tools. However, limited access to diagnostic services in low-income countries and ethical issues related to abortion restrain market growth. Significant opportunities include untapped markets in developing countries and ongoing R&D to expand applications of NIPT to detect genetic mutations and chromosomal microdeletion or duplications.
Key Features of the Study:
- This report provides in-depth analysis of the global Non-invasive Prenatal Testing (NIPT) market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Non-invasive Prenatal Testing (NIPT) market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Illumina, Inc., Natera, Inc., Roche Diagnostics, Ariosa Diagnostics, Verinata Health, Inc., Yourgene Health, Centogene N.V., Eurofins Scientific, F. Hoffmann-La Roche Ltd., LabCorp, Quest Diagnostics, BGI Genomics, MedGenome Labs, Genetic Technologies Limited, and Myriad Genetics, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global Non-invasive Prenatal Testing (NIPT) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Non-invasive Prenatal Testing (NIPT) market
Market Segmentation
Table of Contents
*Browse 32 market data tables and 28 figures on 'Global Non-invasive Prenatal Testing (NIPT) Market' - Global forecast to 2031
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
